IDL Biotech licenses its manual ELISA tumor marker product line to Beckman Coulter Diagnostics | IDL Biotech
IDL Biotech

CLOSE MENU

Articles

Latest News

January 2021

IDL Biotech licenses its manual ELISA tumor marker product line to Beckman Coulter Diagnostics

“IDL Biotech wants to focus on rapid diagnostic tests and automated assays of its tumor markers. By licensing the platform ELISA to Beckman Coulter, we can focus our resources on streamlining and developing the other platforms,” said Gunnar Wahlberg, CEO of IDL Biotech.

IDL Biotech announced it has signed an agreement with Beckman Coulter for licensing IDL’s entire range of manual ELISA tumor markers. The licensing agreement provides Beckman Coulter with global sales rights and enables IDL to sell material for production and to receive royalties. The agreement has been formally countersigned by Immunotech, a Beckman Coulter subsidiary.

 

The tumor markers included in the ELISA platform are TPS®, TPAcyk™, MonoTotal® and UBC®.

Read the full press release here (Swedish)

IDL Biotech includes additional clinics in its ongoing multicenter study for UBC® Rapid in Sweden.

IDL Biotech currently has a number of ongoing clinical studies both internationally and in Sweden, with the aim of demonstrating the clinical benefit of UBC® Rapid in bladder cancer and having the test included as a complement in the follow-up of patients with bladder cancer who are classified as high risk.

IDL Biotech signs distributor agreements in Rwanda, South Sudan and Somalia

IDL Biotech continues to expand in Africa. Today, IDL Biotech has signed a distributor agreement with Roi Scientific Ltd covering Rwanda, South Sudan and Somalia. The agreement covers the sale of TUBEX® TF.

IDL Biotech

Skip this intro